Although the 0.13% market-cap proportion is not massive, the concentration of C-suite/executive-level selling in a narrow window — especially the EVP of North America's $8.90M sale — warrants caution. Option exercises concurrent with sales suggest a liquidity event rather than pure bearish conviction, but the lack of any insider buying from RYTM in recent months amplifies the signal. Monitor next few days for any corporate announcement (data readout, partnership, or financing) that may have prompted this activity; if no news emerges, the selling likely reflects diversification at elevated share prices. Eyes on upcoming Q3 2026 earnings for guidance updates.
Price Chart
Executive Summary
A cluster of insider selling at Rhythm Pharmaceuticals, totaling $9.95M in open-market sales across four senior executives, including the EVP of North America ($8.90M), the Chief Technical Officer ($608K), the Chief Scientific Officer ($182K), and the EVP of International ($257K). Several of these sales are accompanied by same-day option exercises at nominal prices, indicating a possible hedging or tax-optimization motive, but the large aggregate dollar value (0.13% of the $7.9B market cap) is notable for its C-suite breadth and coordination within a three-day window.
Key Financial Metrics
Key Facts
- Total open-market insider selling of $9.95M over 5 trading days (Aug 10–13, 2026).
- EVP of North America Jennifer Lee sold $8.90M (75,834 shares) at a weighted average price of ~$117.38, representing ~89% of the cluster's total value.
- Chief Technical Officer Joseph Shulman sold $608K (5,079 shares) at $119.75.
- Chief Scientific Officer Alastair Garfield sold $402K (7,763 shares) across multiple trades at $116–$119.
- EVP of International Yann Mazabraud sold $257K (2,300 shares) at $111.80.
- Several selling executives also exercised stock options on the same day at deeply in-the-money strike prices ($0, $6.80, $24.29), generating shares for sale with minimal tax withholding.
- Prior 30-day insider activity showed $1.5M in total sales — this cluster triples that dollar amount in a single week.
- Historical performance on RYTM shows strong average +8.25% T+20 alpha across past reports, but the net sell cluster pattern has not been tested on this ticker.
- Market cap of $7.9B makes this $9.95M cluster 0.13% of market cap, just inside the 'modest' proportionality band (0.1–0.5%).
Financial Impact
Insider selling of $9.95M, representing 0.13% of Rhythm Pharmaceuticals' market cap of $7.9B.
Risk Factors
- Insiders may be selling ahead of negative news (e.g., clinical setback, regulatory delay, weak commercial sales for IMCIVREE) that is not yet public.
- No insider purchases for months — one-sided selling direction bias creates overhang sentiment risk.
- Even if sales are 10b5-1 plan-driven, the lack of context on plan adoption dates leaves the market to assign adverse selection probability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RYTM-1787120890214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access